News

The Dow’s industrial-era anchors are quietly outpacing the broader market. Over the past year, the SPDR S&P 500 ETF Trust (NYSEARCA: SPY) returned 24.37%, and the Dow tracker returned 20.22%. Three “old economy” Dow components have left both benchmarks in the dust, and they share more than just a ticker on the same index. What ... These 3 ‘Old Economy’ Dow Stocks Are Quietly Crushing the Market, and Here’s What They All Share

CVS Health (NYSE:CVS) is facing lawsuits from multiple health systems that allege the company diverted hundreds of millions of dollars in savings tied to the federal 340B drug discount program. At the same time, CVS Health is expanding access to GLP-1 weight management drugs through new formulary decisions, including the reintroduction of Zepbound and removal of barriers for Foundayo. These developments come as pharmacy benefit manager practices receive increased attention from regulators...

The latest trading day saw CVS Health (CVS) settling at $95.93, representing a +1.17% change from its previous close.

After a brutal stretch, the insurance behemoth came roaring back. But does the underlying data fully support the sustainability of this momentum.

CVS Health (CVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

It's another step in Eli Lilly's quest to cement its lead in the chronic weight management market.

Dow Jones futures fell slightly after hours, along with S&P 500 futures and Nasdaq futures. The May jobs report is on tap before Friday's open. The stock market saw the Dow Jones jump to a record high, aided by lower oil prices and Treasury yields.

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up +0.41%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +1.73%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.53%. June E-mini S&P futures (ESM26 ) rose +0.36%, and June E-mini Nasdaq futures...

Health insurers are running higher in Thursday afternoon trading after a wave of bullish Wall Street analyst notes on the managed-care sector, centered on UnitedHealth, citing softer medical cost and utilization trends plus potential AI efficiency upside. Humana (NYSE:HUM) stock is leading the move, up 6% to $348, with UnitedHealth Group (NYSE:UNH) stock up 5% ... Humana Jumps 6%, UnitedHealth Climbs 5%, Cigna Rises 4% as Analysts Cheer Softer Medical Cost Trends

Shares of UnitedHealth Group receive votes of confidence from analysts at BofA Securities and Morgan Stanley.

CVS Health (CVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

UnitedHealth (UNH), CVS Health (CVS) and Cigna (CI) are among the managed-care companies that could

The S&P 500 Index ($SPX ) (SPY ) today is up +0.02%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.49%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.90%. June E-mini S&P futures (ESM26 ) are up +0.02%, and June E-mini Nasdaq futures...

The S&P 500 Index ($SPX ) (SPY ) today is down -0.16%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.41%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.23%. June E-mini S&P futures (ESM26 ) are down -0.14%, and June E-mini Nasdaq futures...

UnitedHealth Group, CVS Health and other S&P 500 health insurance giant rallied on Thursday morning after price-target hikes from Morgan Stanley and a UNH upgrade from BofA. The analysts highlighted moderating health care utilization trends and a tailwind to profitability from deploying AI.

The average brokerage recommendation (ABR) for CVS Health (CVS) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

In late May 2026, Salesforce reported first-quarter fiscal 2027 results with revenue of US$11.13 billion and net income of US$2.11 billion, alongside updated full-year guidance and a US$0.44 quarterly dividend declaration. Around the same time, the company deepened its AI push with a roughly US$5 billion stake in Anthropic, the planned acquisition of Contentful, expanded Agentforce deployments with clients like CVS Health, and fresh equity capacity via a US$10.32 billion shelf registration...

CVS Health has outpaced the S&P 500 Index over the past year, and analysts are highly optimistic about the stock’s prospects.

Smart beta had a confusing first half of 2026, as momentum cooled after a strong 2025, low-volatility lagged a market that kept grinding higher, and dividend growth funds got squeezed by another leg up in yields. The strategies that held their ground share a common screen: companies that generate real cash and earn returns above ... Three Free Cash Flow and Quality ETFs Quietly Beating Every Other Smart Beta Strategy in 2026

Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health.

AbbVie, CVS Health, and Verizon Communications are all high-yielding stocks with attractive valuations and robust financials.

These aren't the most exciting businesses, but they have a lot to offer to long-term investors.

Growth, not yield, is the deciding factor.

CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Salesforce (NYSE:CRM) expanded its Agentforce Health partnership with CVS Health, described as its largest Agentforce agreement in regulated industries. The company launched a Forward Deployed Engineering partner network with TTEC Digital to support AI agent deployments. Salesforce also extended AI powered customer engagement capabilities across several sectors, including healthcare and other regulated markets. Salesforce, trading at $191.1, has seen mixed share performance, with the stock...

CVS Health (NYSE:CVS) received the 2026 Newsweek AI Impact Award for its AI-driven prescription technology. The company was recognized for AI tools that standardize prescription inputs and support safer medication dispensing across its pharmacy network. CVS Health Ventures made a major investment in healthcare AI startup H1 to improve provider data accuracy. For a company that operates a large US pharmacy and health services network, CVS Health’s latest AI moves relate directly to its core...

CVS Caremark has granted preferred formulary status to both Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo. This decision reverses Wegovy's prior commercial advantage within CVS Caremark's GLP-1 obesity drug coverage. The change affects access and competitive positioning for GLP-1 obesity therapies in CVS Caremark's network. Novo Nordisk, listed as CPSE:NOVO B, is a key player in GLP-1 based therapies, with Wegovy at the center of its obesity drug portfolio. CVS Caremark's move...

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.

CVS restores broader Zepbound coverage after price cuts, putting Wegovy and Zepbound on equal footing.

CVS Health (NYSE:CVS) has launched Aetna Mental Health On Demand to widen access to virtual behavioral health services. The company is expanding its pharmacy benefits with updated GLP-1 formulary options for weight loss medications. CVS Health has broadened its AI-focused collaboration with Salesforce to support members and providers through more tailored digital tools. For investors watching NYSE:CVS, these moves sit at the intersection of managed care, retail pharmacy, and digital health...